請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63963完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 楊銘欽,鍾國彪 | |
| dc.contributor.author | Hui-Ru Chang | en |
| dc.contributor.author | 張慧如 | zh_TW |
| dc.date.accessioned | 2021-06-16T17:24:35Z | - |
| dc.date.available | 2012-09-17 | |
| dc.date.copyright | 2012-09-17 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-08-16 | |
| dc.identifier.citation | 1. 民國98年癌症登記報告 [http://www.bhp.doh.gov.tw/BHPnet/Portal/StatisticsShow.aspx?No=201206210001]
2. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. The New England journal of medicine 2005, 352(5):476-487. 3. 萬德森: 重視結腸直腸外科綜合治療的規範化. 外科理論與實踐 2006, 11(6):475-477. 4. Wexner SD, Rotholtz NA: Surgeon influenced variables in resectional rectal cancer surgery. Dis Colon Rectum 2000, 43(11):1606-1627. 5. 江支銘: 直腸癌手術治療之現況. 中華民國癌症醫學會雜誌 2008, 24(3):167-171. 6. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D et al: American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. J Clin Oncol 2009. 7. Bufalari A, Giustozzi G, Burattini MF, Servili S, Bussotti C, Lucaroni E, Ricci E, Sciannameo F: Rectal cancer surgery in the elderly: a multivariate analysis of outcome risk factors. J Surg Oncol 2006, 93(3):173-180. 8. Kerrigan M, Howlader N, Mandelson MT, Harrison R, Mansley EC, Ramsey SD: Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care 2005, 43(10):1043-1048. 9. Renzulli P, Lowy A, Maibach R, Egeli RA, Metzger U, Laffer UT: The influence of the surgeon's and the hospital's caseload on survival and local recurrence after colorectal cancer surgery. Surgery 2006, 139(3):296-304. 10. Heriot AG, Tekkis PP, Smith JJ, Cohen CR, Montgomery A, Audisio RA, Thompson MR, Stamatakis JD: Prediction of postoperative mortality in elderly patients with colorectal cancer. Dis Colon Rectum 2006, 49(6):816-824. 11. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006, 98(9):610-619. 12. Wattchow DA, Weller DP, Esterman A, Pilotto LS, McGorm K, Hammett Z, Platell C, Silagy C: General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006, 94(8):1116-1121. 13. Marusch F, Koch A, Schmidt U, Pross M, Gastinger I, Lippert H: Hospital caseload and the results achieved in patients with rectal cancer. Br J Surg 2001, 88(10):1397-1402. 14. Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB: Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol 2003, 83(2):68-78; discussion 78-69. 15. Ouellette JR, Small DG, Termuhlen PM: Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 2004, 8(8):1061-1067. 16. Adjuvant therapy for patients with colon and rectal cancer. National Institutes of Health. Conn Med 1990, 54(10):573-581. 17. Minsky BD, Coia L, Haller D, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J et al: Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. Int J Radiat Oncol Biol Phys 1998, 41(1):21-27. 18. Hodder RJ, Ballal M, Selvachandran SN, Cade D: Variations in the evaluation of colorectal cancer risk. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2005, 7(3):254-262. 19. Glimelius B: Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Ups J Med Sci 2012, 117(2):225-236. 20. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001, 358(9290):1291-1304. 21. Chen Y, Qiu Z, Kamruzzaman A, Snodgrass T, Scarfe A, Bryant HE: Survival of metastatic colorectal cancer patients treated with chemotherapy in Alberta (1995-2004). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2010, 18(2):217-224. 22. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H: Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22(23):4829-4836. 23. Welch HG, Miller ME, Welch WP: Physician profiling. An analysis of inpatient practice patterns in Florida and Oregon. The New England journal of medicine 1994, 330(9):607-612. 24. Grytten J, Sorensen R: Practice variation and physician-specific effects. J Health Econ 2003, 22(3):403-418. 25. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, Colditz GA: Comparison of risk factors for colon and rectal cancer. International journal of cancer Journal international du cancer 2004, 108(3):433-442. 26. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767. 27. 莫惠珍: 大腸直腸癌病患身心社會調適與社會支持之相關性探討. 台北: 國立陽明大學; 2002. 28. Vasen HF, Mecklin JP, Khan PM, Lynch HT: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34(5):424-425. 29. 朱冠安: 利用生物指標對不同的直腸癌放射治療計畫比較. 台中: 中臺科技大學; 2007. 30. Ainbinder DJ, Esmaeli B, Groo SC, Finger PT, Brooks JP: Introduction of the 7th edition eyelid carcinoma classification system from the American Joint Committee on Cancer-International Union Against Cancer staging manual. Arch Pathol Lab Med 2009, 133(8):1256-1261. 31. TNM Classification of Malignant Tumors, International Union Against Cancer edn. New York: Wiley-Liss, Inc; 2002. 32. Rudy DR, Zdon MJ: Update on colorectal cancer. Am Fam Physician 2000, 61(6):1759-1770, 1773-1754. 33. Eisenberg JM: Physician utilization: the state of research about physicians' practice patterns. Med Care 2002, 40(11):1016-1035. 34. Physician Payment Review Commission. In. Edited by Congress ARt. Washington, DC; 1988. 35. Berenson R, Holahan J: Sources of the growth in Medicare physician expenditures. JAMA : the journal of the American Medical Association 1992, 267(5):687-691. 36. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 2006, 101(10):2308-2318. 37. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M, Carter WB: Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 2001, 15(10):1296-1306; discussion 1310-1291, 1314. 38. Visser O, Bakx R, Zoetmulder FA, Levering CC, Meijer S, Slors JF, van Lanschot JJ: The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: a population-based study in Greater Amsterdam. J Surg Oncol 2007, 95(6):447-454. 39. Compton CC: Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006, 130(3):318-324. 40. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P: Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994, 344(8924):707-711. 41. 謝郁珠: 直腸癌切除術後醫療利用與醫療品質相關因素之探討. 台北: 國立陽明大學; 2006. 42. Habr-Gama A, Perez RO, Proscurshim I, Nunes Dos Santos RM, Kiss D, Gama-Rodrigues J, Cecconello I: Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008, 71(4):1181-1188. 43. Seymour MT: Colorectal cancer: treatment of advanced disease. Cancer Treat Rev 1998, 24(2):119-131. 44. Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R et al: Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009, 20(5):906-912. 45. Gensheimer M, Jones CA, Graves CR, Merchant NB, Lockhart AC: Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemother Pharmacol 2009, 63(2):371-373. 46. Malik I, Hussein F, Bush D, Alqaisi M, Bernal P, Byrd J, Garberoglio C: A Phase I Study of Capecitabine, Irinotecan, Celecoxib, and Radiation as Neoadjuvant Therapy of Patients With Locally Advanced Rectal Cancer. Am J Clin Oncol 2009. 47. Kurt M, Ozkan L, Kurt E, Cetintas SK, Aygun S, Ercan I, Yilmazlar T, Memik F: Comparison of protracted infusion 5-fluorouracil and capecitabine in adjuvant chemoradiotherapy for rectal cancer. Hepatogastroenterology 2008, 55(85):1158-1163. 48. Liauw SL, Minsky BD: The use of capecitabine in the combined-modality therapy for rectal cancer. Clin Colorectal Cancer 2008, 7(2):99-104. 49. 黃敬倫: 轉移性大腸直腸癌的治療. 中華癌醫會誌 2008, 24(3):199-202. 50. Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PP: Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998, 42(1):51-57. 51. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England journal of medicine 2004, 351(17):1731-1740. 52. Kachnic LA: Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol 2006, 33(6 Suppl 11):S64-69. 53. Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Soreide O: Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 2004, 47(1):48-58. 54. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. 55. Glynne-Jones R, Sebag-Montefiore D: Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. J Clin Oncol 2006, 24(28):4664-4665; author reply 4665-4666. 56. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L: Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005, 23(24):5620-5627. 57. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D, Sargent D: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001, 93(8):583-596. 58. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S: Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012, 3:CD004078. 59. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA : the journal of the American Medical Association 1990, 264(11):1444-1450. 60. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22(10):1797-1806. 61. 王照元: 大腸直腸癌的輔助性化學治療. 中華民國癌症醫學會雜誌 2008, 24(3):180-184. 62. Penopoulos V, Handolias M, Avgerinos A, Maris T, Ilias T, Issopoulos N, Christianopoulos G, Betsis D, Vrettou E, Kitis G et al: A short course of preoperative radiotherapy improves prognosis of operable rectal carcinoma: a case control study. Hepatogastroenterology 2008, 55(85):1280-1287. 63. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. The New England journal of medicine 1997, 336(14):980-987. 64. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH: Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002, 26(3):350-357. 65. Gollins S: Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2010, 12 Suppl 2:2-24. 66. Frykholm GJ, Glimelius B, Pahlman L: Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993, 36(6):564-572. 67. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E: A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003, 42(5-6):476-492. 68. Douglass HO, Jr., Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stablein DM, Bruckner HW: Survival after postoperative combination treatment of rectal cancer. The New England journal of medicine 1986, 315(20):1294-1295. 69. Stryker SJ, Kiel KD, Rademaker A, Shaw JM, Ujiki GT, Poticha SM: Preoperative 'chemoradiation' for stages II and III rectal carcinoma. Arch Surg 1996, 131(5):514-518; discussion 518-519. 70. Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A et al: Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 2004, 60(4):1098-1105. 71. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H et al: Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012, 30(16):1926-1933. 72. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M: Preoperative radiotherapy for resectable rectal cancer - A meta-analysis. Jama-Journal of the American Medical Association 2000, 284(8):1008-1015. 73. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U: Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. Journal of Clinical Oncology 2005, 23(24):5644-5650. 74. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJT, Pahlman L, Glimelius B, van Krieken JHJM et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. New England Journal of Medicine 2001, 345(9):638-646. 75. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H et al: Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. Journal of Clinical Oncology 2012, 30(16):1926-1933. 76. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93(10):1215-1223. 77. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW et al: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246(5):693-701. 78. Kariv Y, Kariv R, Hammel JP, Lavery IC: Postoperative radiotherapy for stage IIIA rectal cancer: is it justified? Dis Colon Rectum 2008, 51(10):1459-1466. 79. Chang CY, Kim HC, Park YS, Park JO, Choi DH, Park HC, Cho YB, Yun SH, Lee WY, Chun HK: The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer. J Surg Oncol 2012, 105(3):244-248. 80. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. The New England journal of medicine 2006, 355(11):1114-1123. 81. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. Journal of Clinical Oncology 2006, 24(28):4620-4625. 82. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS et al: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373(9666):811-820. 83. Gray R, Hills R, Stowe R, Clarke M, Peto R, Buyse M, Piedbois P, Grp CCC: Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001, 358(9290):1291-1304. 84. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ et al: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27(31):5124-5130. 85. Huh JW, Lim SW, Kim HR, Kim YJ: Effects of postoperative adjuvant radiotherapy on recurrence and survival in stage III rectal cancer. J Gastrointest Surg 2011, 15(6):963-970. 86. Wood WR, Ament RP, Kobrinski EJ: A foundation for hospital case mix measurement. Inquiry 1981, 18(3):247-254. 87. Polite BN, Dignam JJ, Olopade OI: Colorectal cancer model of health disparities: understanding mortality differences in minority populations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24(14):2179-2187. 88. Bulut O, Brink L, Jess P: [Laparoscopy-assisted colon resection. A prospective study with short-term results and 12-38 months' follow-up]. Ugeskr Laeger 2005, 167(32):2882-2886. 89. Janson M, Bjorholt I, Carlsson P, Haglind E, Henriksson M, Lindholm E, Anderberg B: Randomized clinical trial of the costs of open and laparoscopic surgery for colonic cancer. Br J Surg 2004, 91(4):409-417. 90. Monz BU, Konig HH, Leidl R, Staib L, Link KH: Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics 2003, 21(10):709-719. 91. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA : the journal of the American Medical Association 2002, 287(3):321-328. 92. Varpe P, Huhtinen H, Rantala A, Salminen P, Rautava P, Hurme S, Gronroos J: Quality of life after surgery for rectal cancer with special reference to pelvic floor dysfunction. Colorectal Dis 2009. 93. Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993, 118(8):622-629. 94. Wilson IB, Cleary PD: Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA : the journal of the American Medical Association 1995, 273(1):59-65. 95. Scuffham PA, Whitty JA, Mitchell A, Viney R: The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4. Pharmacoeconomics 2008, 26(4):297-310. 96. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS: Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989, 7(1):36-44. 97. Hwang JS, Tsauo JY, Wang JD: Estimation of expected quality adjusted survival by cross-sectional survey. Stat Med 1996, 15(1):93-102. 98. Hwang JS, Wang JD: Integrating health profile with survival for quality of life assessment. Qual Life Res 2004, 13(1):1-10; discussion 11-14. 99. Hwang JS, Wang JD: Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med 1999, 18(13):1627-1640. 100. Tsauo JY, Hwang JS, Chiu WT, Hung CC, Wang JD: Estimation of expected utility gained from the helmet law in Taiwan by quality-adjusted survival time. Accid Anal Prev 1999, 31(3):253-263. 101. 鄭智文: 全民健保制度下醫院處方集對結腸直腸癌用藥可近性之影響探討. 臺灣大學; 2010. 102. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA et al: Effective Surgical Adjuvant Therapy for High-Risk Rectal-Carcinoma. New England Journal of Medicine 1991, 324(11):709-715. 103. Boulis-Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N: Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984, 53(9):1811-1818. 104. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. The New England journal of medicine 1991, 324(11):709-715. 105. Tveit KM, Guldvog I, Hagen S, Trondsen E, Harbitz T, Nygaard K, Nilsen JB, Wist E, Hannisdal E: Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg 1997, 84(8):1130-1135. 106. Hall WH: Adjuvant Therapy for Patients with Colon and Rectal-Cancer. Jama-Journal of the American Medical Association 1990, 264(11):1444-1450. 107. Minsky BD: Adjuvant therapy for rectal cancer--a good first step. The New England journal of medicine 1997, 336(14):1016-1017. 108. Chao M, Gibbs P, Tjandra J, Cullinan M, McLaughlin S, Faragher I, Skinner I, Jones I: Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer. ANZ J Surg 2005, 75(5):286-291. 109. Srinivasaiah N, Joseph B, Mackey P, Monson JR: How do we manage early rectal cancer? A national questionnaire survey among members of the ACPGBI after the preliminary results of the MRC CR07/NCIC CO16 randomized trial. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2008, 10(4):357-362. 110. Masya LM, Young JM, Solomon MJ, Harrison JD, Dennis RJ, Salkeld GP: Preferences for Outcomes of Treatment for Rectal Cancer: Patient and Clinician Utilities and Their Application in an Interactive Computer-Based Decision Aid. Diseases of the Colon & Rectum 2009, 52(12):1994-2002. 111. Martijn H, Vulto JCM: Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? European Journal of Cancer 2007, 43(15):2301-2306. 112. Lemmens VEPP, Janssen-Heijnen MLG, Verheij CDGW, Houterman S, van Driel OJR, Coebergh JWW: Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. British Journal of Surgery 2005, 92(5):615-623. 113. Scott NA, Susnerwala S, Gollins S, Myint AS, Levine E: Preoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2009, 11(3):245-248. 114. Kennedy ED, Schmocker S, Victor C, Baxter NN, Kim J, Brierley J, McLeod RS: Do Patients Consider Preoperative Chemoradiation for Primary Rectal Cancer Worthwhile? Cancer 2011, 117(13):2853-2862. 115. Willett CG, Compton CC, Shellito PC, Efird JT: Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer 1994, 73(11):2716-2720. 116. Habr-Gama A, Perez RO, Kiss DR, Rawet V, Scanavini A, Santinho PM, Nadalin W: Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology 2004, 51(60):1703-1707. 117. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR: Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 2002, 97(5):1228-1234. 118. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE: A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996, 88(15):1039-1045. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63963 | - |
| dc.description.abstract | 前言：直腸癌是國內高盛行癌症之一，雖然近來在治療方法已有長足進展，但死亡率及復發率仍高，因此直腸癌的治療效益持續受到關注。然而若僅針對個別之治療方法進行探討，將過於繁雜又無法有效推估預後，因此可由整體治療模式著手，能較完整評估病人的治療效益。
目的：有鑑於直腸癌的理想治療模式仍無定論，因此本研究以直腸癌切除術病人為例，探討目前國內常見之直腸癌輔助治療模式，以及該等模式對病人存活及生活品質校正存活時間影響的差異。 方法：本研究以病人術前及術後有無接受放射線治療及化學治療來界定治療模式種類，並以行政院衛生署健康統計資料中2005-2007年間首次進行直腸癌切除術患者之健保醫療利用資料來檢視常見之治療模式，另進一步運用存活分析方法探討該等治療模式對病人整體存活率影響的差異。再者，本研究另使用EQ-5D問卷調查台灣北部二家醫學中心2006-2009年間直腸癌切除術患者之生活品質，以蒙地卡羅估計法估算與比較各類治療模式病人的生活品質校正存活時間。 結果：本研究歸類常見之直腸癌治療模式包括模式1：術前術後均無輔助治療、模式2：術後放化療、模式3：術後化療、模式4：術前術後均放化療、模式5：術前放化療且術後化療、模式6：術前放療且術後放化療、模式7：術前放化療、模式8：術前放療且術後化療。在各模式對病人預後的影響上，早期個案以接受模式7 (術前放化療)或模式1 (術前術後均無輔助治療)者之整體存活率及生活品質校正存活時間有較佳的表現；而晚期個案則以接受模式6 (術前放療且術後放化療)、模式5 (術前放化療且術後化療)、或模式4 (術前術後均放化療)個案之預後佳。此外，本研究結果亦發現最常見之治療模式(模式2) 之存活率及生活品質校正存活時間並非最佳。 結論：本研究結果顯示不同治療模式確會為病人帶來不同之治療效益。由於本研究不僅使用全國性資料來分析治療模式對直腸癌整體存活率之影響，並進一步以生活品質進行存活時間之校正，故研究結果值得醫療服務提供者及衛生主管機關於醫療服務提供或衛生政策制訂之參考。 | zh_TW |
| dc.description.abstract | Introductions: Rectal cancer is one of the most incident forms of cancer in Taiwan. Mortality and recurrence rates of rectal cancer are still high despite the improvements in treatments, and therefore there are increasing concerns regarding the benefits of treatments. The approach to analyze each treatment complicates the studies and cannot estimate the prognosis precisely. Instead of specific treatment, focusing on patterns of care is considered to be more complete.
Objectives: To explore the frequent patterns of pre- and post-operation adjuvant therapies for rectal cancer and to evaluate the effects of these patterns on survival and quality adjusted survival time. Methods: First, the nationwide Health Insurance Database in Taiwan was used to explore frequent patterns of care for patients received resection for rectal cancer during 2005-2007, and further survival analysis was used to determine if patterns of care affecting overall survival. Secondly, patients received resection for rectal cancer from two medical centers during 2006-2009 were retrieved. Their quality of life was measured using the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D) and Monte Carlo method was applied to estimate the quality adjusted survival time for patients received different patterns of care. Results: The frequent patterns of care for rectal cancer were pattern of resection without any adjuvant therapy, pattern of postoperative radiotherapy and chemotherapy, pattern of postoperative chemotherapy, pattern of pre- and postoperative radiotherapy and chemotherapy, pattern of preoperative radiotherapy and chemotherapy and postoperative chemotherapy, pattern of preoperative radiotherapy and postoperative radiotherapy and chemotherapy, pattern of preoperative radiotherapy and chemotherapy, and pattern of preoperative radiotherapy and postoperative chemotherapy. Survival and quality adjusted survival time of patients with early-stage rectal cancer received pattern of preoperative radiotherapy and chemotherapy or pattern of resection without any adjuvant therapy were better than that of other patterns. Survival and quality adjusted survival time of patients with advanced-stage rectal cancer received the pattern of preoperative radiotherapy and postoperative radiotherapy and chemotherapy were better than that of other patterns. Conclusions: The present study shows that there are differences in the effects of frequent patterns of care on prognosis for rectal cancer patients. The findings can be implications for health care policy and practice. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T17:24:35Z (GMT). No. of bitstreams: 1 ntu-101-D94843002-1.pdf: 3875046 bytes, checksum: 818aa80a93596d3ae48fed61ed5211b4 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
誌 謝 ii 中文摘要 iii Abstract v 第一章 緒論 1 第一節 研究緣起 1 第二節 研究目的與研究問題 5 第三節 研究重要性及預期貢獻 6 第二章 文獻探討 7 第一節 直腸癌簡介與分期 7 第二節 治療模式與直腸癌處置方法之探討 10 第三節 各類直腸癌輔助治療及對預後結果之影響 16 第四節 直腸癌預後結果影響因子 23 第五節 直腸癌的預後結果測量指標 26 第六節 生活品質校正存活時間之簡介 30 第三章 研究方法 33 第一節 研究設計與研究架構 33 第二節 研究假說 36 第三節 研究對象與資料來源 37 第四節 研究變項的操作型定義 40 第五節 資料分析方法 42 第四章 研究結果 43 第一節 描述性統計 43 第二節Kaplan-Meier 雙變項分析 46 第三節 Cox Regression多變項分析 55 第四節生活品質校正存活時間預估 60 第五章 討論 80 第一節 研究資料與研究方法之討論 80 第二節 研究假說之驗證 83 第三節 研究結果之討論 85 第四節 研究限制 89 第六章 結論與建議 90 第一節 結論 90 第二節 建議 91 參考文獻 92 附錄一 個案醫院臨床試驗核准函-1 103 附錄二 個案醫院臨床試驗核准函-2 105 附錄三 EQ-5D生活品質問卷 106 附錄四 日本EQ-5D Value Set 109 | |
| dc.language.iso | zh-TW | |
| dc.subject | 直腸癌 | zh_TW |
| dc.subject | 治療模式 | zh_TW |
| dc.subject | 輔助治療 | zh_TW |
| dc.subject | 生活品質 | zh_TW |
| dc.subject | 存活分析 | zh_TW |
| dc.subject | quality of life | en |
| dc.subject | pattern of care | en |
| dc.subject | rectal cancer | en |
| dc.subject | adjuvant therapy | en |
| dc.subject | survival analysis | en |
| dc.title | 癌症術前及術後輔助治療模式對存活與生活品質之影響—以直腸癌切除術病人為例 | zh_TW |
| dc.title | Effects of Patterns of Neoadjuvant and Adjuvant Therapy on Survival and Quality of Life – Using Patients Received Resection for Rectal Cancer as an Example | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 張金堅,李玉春,鄭守夏 | |
| dc.subject.keyword | 直腸癌,治療模式,輔助治療,生活品質,存活分析, | zh_TW |
| dc.subject.keyword | rectal cancer,pattern of care,adjuvant therapy,quality of life,survival analysis, | en |
| dc.relation.page | 109 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-08-16 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
| 顯示於系所單位： | 健康政策與管理研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 未授權公開取用 | 3.78 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。